Just a few days after a stumble, FDA OKs 12-week dose for Eylea as Regeneron braces for Novartis attack

In perhaps the shortest turnaround from an FDA rejection to an approval, Regeneron says the FDA has flagged their approval to start marketing a new, once-every-12-week dose of Eylea for wet, ager-related macular degeneration.